Presenting at the 2022 AAN Annual Meeting, researchers investigated the longitudinal changes of multimodal biomarkers in the presymptomatic phase of GRN-associated frontotemporal dementia.
Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.
Researchers sought to develop a “roadmap” to early intervention and disease prevention for ALS by observing advances in neurodegenerative diseases with a presymptomatic period.
Using MRI, researchers assessed cortical, subcortical, and cerebellar grey matter atrophy in patients with frontotemporal lobar degeneration disorders, including motor neuron disease, with known genetic mutations.
Researchers evaluated a case study of a patient who was diagnosed with frontotemporal behavioral dementia whose autopsy showed coexistent TDP-43 type A and Alzheimer disease pathologies and cerebrovascular disease.
In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
A physically and mentally active lifestyle may protect against frontotemporal dementia even in people at established genetic risk.
There are currently no treatments available for frontotemporal dementia.
Investigators sought to identify genetic factors that may contribute to the risk for neurodegenerative diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.
